Methotrexate discontinuation in patients with non-systemic forms of juvenile idiopathic arthritis
Pediatric Traumatology, Orthopaedics and Reconstructive Surgery · 25.06.2026 · 14 (2) · 168-176
DOI: 10.17816/ptors705370 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Traumatology, Orthopaedics and Reconstructive Surgery, online erschienen am 25.06.2026. Verfasst von Rinat K. Raupov und 4 weiteren Autor:innen. Die Arbeit nennt 18 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Inactive disease or remission is often achieved on treatment in patients with juvenile idiopathic arthritis (JIA). Methotrexate is the most commonly used disease-modifying antirheumatic drug (DMARD) in JIA, and issues of dosing regimen modification in patients in prolonged remission remain relevant. AIM: To study the outcomes of articular forms of juvenile idiopathic arthritis in patients who received methotrexate therapy and to identify predictors of clinical remission off medication. METHODS: This retrospective study included 155 patients with articular forms of juvenile idiopathic arthritis who received methotrexate therapy. Baseline clinical and laboratory characteristics were assessed, reasons for methotrexate discontinuation were analyzed, and predictors of drug-free remission were identified. RESULTS: Clinical remission on medication was achieved in 69 of 155 (44.5%) patients. A total of 71 of 155 patients discontinued methotrexate: 45 (62.5%) due to remission, 13 (18.1%) due to intolerance, 3 (4.2%) due to elevated liver enzyme levels, 1 (1.4%) due to frequent upper respiratory tract infections, and in 9 cases (12.5%) parents discontinued therapy independently. In the remission discontinuation group, a comparative analysis of baseline characteristics was performed in patients who subsequently developed flare (25 of 35; 71.4%) versus those who did not develop flare (10 of 35; 28.6%) at the time of last follow-up, with exclusion of patients receiving biologic DMARDs at the time of methotrexate discontinuation (n = 4) and those with less than 18 months of follow-up after discontinuation (n = 6). The median time to flare was 9 [4; 20] months. Follow-up duration for patients who did and did not experience flare after methotrexate discontinuation was 25.5 [23.1; 28.6] and 30.4 [22.8; 61.3] months, respectively. Both patient groups were comparable with respect to treatment profile, follow-up duration after methotrexate discontinuation, and baseline clinical and laboratory characteristics. Patients who subsequently experienced flare more frequently received intra-articular corticosteroid injections at disease onset (60% vs. 0%, p 0.001) and had a shorter duration of methotrexate therapy after achieving remission (34 months vs. 44 months, p = 0.079) compared with patients without flare. Most patients with flare (21 of 25; 85%) resumed methotrexate treatment, which was effective in 75% of patients; 7 of 21 patients subsequently required initiation of biologic therapy. CONCLUSION: Patients who did not receive intra-articular corticosteroids at disease onset and had a longer duration of methotrexate therapy after achieving remission demonstrated a lower risk of juvenile idiopathic arthritis flare.
Zitieren
APA
Raupov, R. K., Vissarionov, S. V., Orlova, M. V., Dubko, M. F., & Kostik, M. M. (2026). Methotrexate discontinuation in patients with non-systemic forms of juvenile idiopathic arthritis. Pediatric Traumatology, Orthopaedics and Reconstructive Surgery, 14(2), 168-176. https://doi.org/10.17816/ptors705370
Vancouver
Raupov RK, Vissarionov SV, Orlova MV, Dubko MF, Kostik MM. Methotrexate discontinuation in patients with non-systemic forms of juvenile idiopathic arthritis. Pediatric Traumatology, Orthopaedics and Reconstructive Surgery. 2026;14(2):168-176. doi:10.17816/ptors705370
BibTeX
@article{Raupov2026,
author = {Raupov, Rinat K. and Vissarionov, Sergei V. and Orlova, Mariia V. and Dubko, Margarita F. and Kostik, Mikhail M.},
title = {Methotrexate discontinuation in patients with non-systemic forms of juvenile idiopathic arthritis},
journal = {Pediatric Traumatology, Orthopaedics and Reconstructive Surgery},
year = {2026},
volume = {14},
number = {2},
pages = {168--176},
doi = {10.17816/ptors705370}
}
EUVIMED